Search

Displaying results 3371 - 3380 of 10000 in total
  1. Drug

    Gatralimab

    go.drugbank.com/drugs/DB16528
    Investigational

    Gatralimab is under investigation in clinical trial NCT02389452 (Study of Safety and Efficacy of 6 Ml Synvisc-one (Hylan G-F 20) in Indian Patients With Symptomatic Osteoarthritis of Knee(s) After Initial

  2. Drug

    SARS-CoV-2 virus recombinant spike (S) protein receptor binding domain (RBD) fusion heterodimer (B.1.351-B.1.1.7 strains)

    go.drugbank.com/drugs/DB18705
    Approved

    [L48902] It is intended to elicit protection against Omicron XBB.1.5, one of the dominant circulating SARS-CoV-2 subvariants in 2023. … [A262551] It is produced using recombinant DNA technology in CHO cell lines and is marketed by Hipra Human Health S.L. for the European market.

  3. Drug

    Mitemcinal

    go.drugbank.com/drugs/DB06587
    Investigational

    Mitemcinal (GM-611) is a novel erythromycin-derived prokinetic agent that acts as an agonist at the motilin receptor.

    Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors
  4. Drug

    Ethchlorvynol

    go.drugbank.com/drugs/DB00189
    ApprovedIllicitWithdrawn

    It has been used to treat insomnia, but has been largely superseded and is only offered where an intolerance or allergy to other drugs exists.

  5. Drug

    Veliflapon

    go.drugbank.com/drugs/DB16346
    Investigational

    Veliflapon is under investigation in clinical trial NCT00353067 (Veliflapon (Dg-031)to Prevent Heart Attacks or Stroke in Patients With a History of Heart Attack or Unstable Angina).

  6. Drug

    Navepegritide

    go.drugbank.com/drugs/DB17824
    ApprovedInvestigational

    Achondroplasia, the most prevalent skeletal dysplasia, is caused by a gain-of-function variant in the fibroblast growth factor receptor 3 (FGFR3), which leads to overactive downstream signaling that inhibits … [L56058] Developed to address the clinical limitations of daily therapies, the pegylated nature of navepegritide allows for once-weekly dosing while providing sustained systemic exposure to CNP, which

  7. Drug

    Human papillomavirus type 11 L1 capsid protein antigen

    go.drugbank.com/drugs/DB10300
    ApprovedInvestigational

    It is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) types 6, 11, 16 and 18. … The vaccine is prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Types 6, 11, 16, and 18, which are produced by separate fermentations in recombinant *Saccharomyces

    Mixtures: GARDASIL 0.5 ML IM ENJEKSİYON İÇİN SÜSPANSİYON İÇEREN FLAKON
  8. Drug

    Ataluren

    go.drugbank.com/drugs/DB05016
    ApprovedWithdrawn

    Ataluren is approved for use by the European Medicines Agency to treat Duchenne Muscular Dystrophy in patients aged 5 years and older who are able to walk. … This drug does not yet have approval by the US Food and Drug Administration or by Health Canada for any indications.

    Synonyms: 3-[5-(2-fluorophenyl)-1,2,4-oxadiazol-3-yl]benzoic acid
  9. Drug

    Silicon

    go.drugbank.com/drugs/DB12982
    Approved

    Silicon is under investigation in clinical trial NCT00103246 (Photodynamic Therapy Using Silicon Phthalocyanine 4 in Treating Patients With Actinic Keratosis, Bowen's Disease, Skin Cancer, or Stage I or Stage II Mycosis Fungoides).

    Mixtures: Calcium With Mg Zn Mn Cu CR Si and Vit. C & D, Vegetal Silica 5:1
  10. Drug

    Apararenone

    go.drugbank.com/drugs/DB15024
    Investigational

    Apararenone is under investigation in clinical trial NCT02531568 (Drug Interaction Study of Warfarin and MT-3995).